profit from every $100 of sales.
$0$100
Theravance Biopharma
We have no price for Theravance Biopharma since 25 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$17.03+0.00% today
+21.7% in 1 year
1-year low $13.571-year high $20.74
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $8.35 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Theravance Biopharma sold, what it kept, and what it did with the cash.
Sales went from $51.3 million in 2022 to $107 million in 2025, with $106 million of profit last year.
SalesProfit
Theravance Biopharma handed back 2% of the cash it generated last year.
Buybacks $4M
Free cash flow 2025$238M
Bought back its own shares$4M
Paid as dividends–
Cash vs. debt$168M vs. $43M
Theravance Biopharma vs. similar companies
Theravance Biopharma grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Theravance Biopharma | 8.3× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Theravance Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 51 | 57 | 64 | 107 | |
| – | – | – | – | |
| -79 | -53 | -42 | -4 | |
| -79 | -43 | -38 | 135 | |
| 872 | -55 | -56 | 106 | |
| 11.85 | -1.00 | -1.15 | 2.06 | |
| – | – | – | – | |
| -154.1% | -92.8% | -65.9% | -3.4% | |
| 1,698.5% | -96.1% | -87.6% | 98.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 607 | 382 | 354 | 486 |
| Cash | 298 | 40 | 38 | 168 |
| Total debt | 52 | 49 | 50 | 43 |
| Total liabilities | 166 | 169 | 179 | 189 |
| 442 | 213 | 176 | 297 | |
| 74 | 55 | 49 | 52 | |
| -13.8% | -14.1% | -14.7% | 30.7% | |
| 197.4% | -25.9% | -32.1% | 35.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -187 | -27 | -12 | 239 | |
| 1 | 2 | 0 | 0 | |
| -188 | -29 | -12 | 238 | |
| Dividends paid | – | – | – | – |
| 132 | 200 | 3 | 4 | |
| 40 | 25 | 21 | 18 |
Valuation
- 8.3×
- 6.7×
- –
- 2.9×
- 8.2×
- 3.7×
- 5.6×
- 27.0%
- 12.0%
- 0.0%
Profitability
- –
- -3.4%
- 98.5%
- 7.3%
- -1.3%
- 19.7%
- 43.8%
- 24.3%
- -1.6%
- 29.0%
Growth
- +27.9%
- −44.2%
- +2,109.8%
- –
- −7.7%
Financial health
- -26.9×
- 0.25
- 15.5%
- -3.9×
- 13.14
- 13.14
- 0.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 35%of 946
Bottom 18%of 872
Top 8%of 563
Top 21%of 868
Top 2%of 986
What analysts expect
- Average price target
- $27.00
- Range
- $14.00 – $40.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.10 | 0.03 | −443.6% |
| Mar 19, 2026 | 0.06 | 0.44 | −86.4% |
| Nov 10, 2025 | 0.04 | -0.03 | +233.3% |
| Aug 12, 2025 | -0.08 | -0.14 | +42.9% |
| May 8, 2025 | -0.17 | -0.11 | −54.5% |
| Feb 26, 2025 | -0.05 | -0.05 | +0.0% |
| Nov 12, 2024 | -0.06 | -0.10 | +40.0% |
| Aug 5, 2024 | -0.13 | -0.09 | −44.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
63Pass
Philip Fisher
67Pass
Peter Lynch
57No pass
Joel Greenblatt
59No pass
Charlie Munger
71Pass
Terry Smith
70Pass
Questions about Theravance Biopharma
Is Theravance Biopharma a good stock to buy?
A strong, very profitable business, and the price looks low. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Theravance Biopharma AI analysis
What does Theravance Biopharma do?
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. It is in Biotechnology.
Does Theravance Biopharma pay a dividend?
No. Theravance Biopharma does not pay a dividend at the moment; in 2025 it returned $4.03 million to shareholders by buying back its own shares.
Is Theravance Biopharma stock halal?
Questionable. Theravance Biopharma sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Theravance Biopharma stock done over the past year?
Up 21.7% over the past twelve months, to $17.03. It traded between $13.57 and $20.74 and is 17.9% below its high.
Who are Theravance Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Theravance Biopharma's.
Prices: daily closes to Sep 25, 2026. Fundamentals: company reports via invest-like data.